Barinthus Biotherapeutics Return On Equity vs. Shares Outstanding
| BRNS Stock | 0.89 0.10 10.10% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.39) | Current Value (0.37) | Quarterly Volatility 0.53371522 |
For Barinthus Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Barinthus Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Barinthus Biotherapeutics plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Barinthus Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Barinthus Biotherapeutics plc over time as well as its relative position and ranking within its peers.
Barinthus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Barinthus Biotherapeutics. If investors know Barinthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Barinthus Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.384 | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Barinthus Biotherapeutics is measured differently than its book value, which is the value of Barinthus that is recorded on the company's balance sheet. Investors also form their own opinion of Barinthus Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Barinthus Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Barinthus Biotherapeutics' market value can be influenced by many factors that don't directly affect Barinthus Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Barinthus Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Barinthus Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Barinthus Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Barinthus Biotherapeutics Shares Outstanding vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Barinthus Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Barinthus Biotherapeutics value to that of its competitors to determine the firm's financial worth. Barinthus Biotherapeutics plc is number one stock in return on equity category among its peers. It also is number one stock in shares outstanding category among its peers . At this time, Barinthus Biotherapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Barinthus Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Barinthus Shares Outstanding vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Barinthus Biotherapeutics |
| = | -0.33 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Barinthus Biotherapeutics |
| = | 40.23 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Barinthus Shares Outstanding Comparison
Barinthus Biotherapeutics is currently under evaluation in shares outstanding category among its peers.
Barinthus Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Barinthus Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Barinthus Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Barinthus Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Barinthus Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -23.3 M | -22.1 M | |
| Operating Income | -83.9 M | -79.7 M | |
| Income Before Tax | -76.5 M | -72.7 M | |
| Total Other Income Expense Net | 7.4 M | 7.8 M | |
| Net Loss | -45.8 M | -48.1 M | |
| Net Loss | -73.4 M | -69.8 M | |
| Income Tax Expense | -3.2 M | -3 M | |
| Net Interest Income | 3.6 M | 3.8 M | |
| Interest Income | 3.6 M | 1.9 M | |
| Net Loss | -77.3 M | -73.5 M | |
| Non Operating Income Net Other | -2.9 M | -3.1 M | |
| Change To Netincome | 27.5 M | 28.9 M | |
| Net Loss | (1.91) | (2.01) | |
| Income Quality | 0.69 | 0.73 | |
| Net Income Per E B T | 0.96 | 1.62 |
Barinthus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Barinthus Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Barinthus Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Barinthus Biotherapeutics' important profitability drivers and their relationship over time.
Use Barinthus Biotherapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Barinthus Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Barinthus Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Barinthus Biotherapeutics Pair Trading
Barinthus Biotherapeutics plc Pair Trading Analysis
The ability to find closely correlated positions to Barinthus Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Barinthus Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Barinthus Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Barinthus Biotherapeutics plc to buy it.
The correlation of Barinthus Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Barinthus Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Barinthus Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Barinthus Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Barinthus Biotherapeutics position
In addition to having Barinthus Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Silver Thematic Idea Now
Silver
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.